pembrolizumab
KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer
KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024
Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%
Ivonescimab, Keytruda, Non-Small Cell Lung Cancer (NSCLC), Phase 3 Trial, HARMONi-2, PD-L1 Positive, Pembrolizumab, Summit Therapeutics, Akeso.
FDA Approves Keytruda for Primary Advanced or Recurrent Endometrial Carcinoma and Skyrizi for Ulcerative Colitis
Keytruda, pembrolizumab, endometrial carcinoma, Skyrizi, risankizumab-rzaa, ulcerative colitis, FDA approval
FDA Approves Pembrolizumab and Durvalumab for Endometrial Cancer Treatment
FDA, Pembrolizumab, Durvalumab, Endometrial Cancer, Immunotherapy, Chemotherapy